Sign in

CIK 0001714899

  • Large accelerated filer

Denali Therapeutics Inc.

Sign in to watch
Ticker
DNLI
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
463872213
Phone
+1 650-866-8547
Business address
161 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080
  1. 4 Open-market sale COFO and Secretary sold 2,522 shares at $23.17 ($58,435)
  2. 4 Open-market sale Chief Medical Officer sold 2,522 shares at $23.22 ($58,561)
  3. 4 Open-market sale Chief Medical Officer sold 2,478 shares at $22.60 ($56,003)
  4. 4 Open-market sale COFO and Secretary sold 2,478 shares at $22.59 ($55,978)
  5. 4 Open-market sale President and CEO sold 2,309 shares at $22.59 ($52,160)
  6. 4 Open-market sale Director sold 1,419 shares at $22.60 ($32,069)
  7. 4 Planned sale Director sold 1,666 shares at $24.30 ($40,484)
  8. 4 Planned sale Chief Medical Officer sold 2,768 shares at $23.79 ($65,851)
  9. 4 Open-market sale COFO and Secretary sold 2,772 shares at $23.67 ($65,613)
  10. 4 Open-market sale President and CEO sold 2,526 shares at $25.03 ($63,226)
  11. 4 Open-market sale Chief Medical Officer sold 2,857 shares at $24.15 ($68,997)
  12. 4 Open-market sale COFO and Secretary sold 2,853 shares at $24.18 ($68,986)
  13. 4 Open-market sale COFO and Secretary sold 19,702 shares at an average $29.80 ($587,157)
  14. 4 Planned sale Director sold 1,666 shares at $29.60 ($49,314)
  15. 4 Planned sale Director sold 1,666 shares at an average $29.84 ($49,709)
  16. 4 Open-market sale President and CEO sold 50,000 shares at $31.40 ($1,570,000)
  17. 4 Grant or award Director acquired 4,216 shares (grant or award)
  18. 4 Grant or award Director acquired 4,216 shares (grant or award)
  19. 4 Grant or award Director acquired 4,216 shares (grant or award)
  20. 4 Grant or award Director acquired 4,216 shares (grant or award)

Page 6 of 22 · 436 filings